Platelet Transfusions in Hematopoietic Stem Cell Transplantation (The PATH Trial)
Status:
Not yet recruiting
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
It is hypothesized that a strategy using prophylactic oral and intravenous Tranexamic Acid
(TXA) with therapeutic platelet transfusions (if required) is safe and more effective than
prophylactic platelet transfusions in patients undergoing an autologous hematopoietic stem
cell transplantation (ASCT).